-
Exhibition at the University of Oxford's BioEscalator(Post)
Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Protocole ELISA contre les anticorps hétérophiles en clinique et labo(Post)Protocole ELISA contre les anticorps hétérophiles en clinique et labo Un résultat Elisa qui ne colle pas au tableau clinique évoque d’abord une interférence par anticorps hétérophiles, surtout sur un
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
Business Development Manager, UK(Page) Ladiratuzumab Vedotin: Targeting TNBC with Next-Gen ADC Therapy(Post)Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t
Assay Genie Mission(Page)Assay Genie Mission | Making Scientists Smile
CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 %(Post)CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 % Le %CV en ELISA se calcule ainsi : (écart-type ÷ moyenne) × 100. Visez un CV intra-plaque inférieur à 10 % (idéalement sous 8 %) et un
Unconventional T Cells: Gamma Delta, iNKT and MAIT(Page) B-Cell Depletion and the BAFF-APRIL Axis(Page) Évitez la rupture de réactifs en 6 actions pour gestionnaires labo(Post)Évitez la rupture de réactifs en 6 actions pour gestionnaires labo Pour éviter la majorité des ruptures de réactifs, auditez votre inventaire critique, fixez des seuils de commande calculés sur le dé
The Environmental Shift: How Climate Change and Biodiversity Loss are Driving the Hantavirus Surge(Post)The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt
Valider en labo vos anticorps pour western blot : testez 2–3 dilutions(Post)Valider en labo vos anticorps pour western blot : testez 2–3 dilutions Pour un Western blot fiable, choisissez un anticorps validé sur des lysats biologiques pertinents, plutôt qu’un anticorps choisi
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer(Post)Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
4 étapes pour des comptes rendus ELISA défendables en laboratoire(Post)Un compte rendu ELISA exploitable réunit l’objectif de l’essai, la référence et le lot du kit, la méthode suivie, les densités optiques brutes, le modèle d’ajustement retenu (4PL ou 5PL) et les fa
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Metabolic Exhaustion: How Mitochondrial Dysfunction Sabotages CAR-T Cell Therapy in Solid Tumors(Post)Imagine engineering a patient's own immune cells into precision-guided missiles against cancer—cells that can seek out and destroy tumors with remarkable specificity. This is the promise of CAR-T cell
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Plonmarlimab: Advancing Anti-GM-CSF Therapy in Inflammatory Diseases(Post)Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Red Blood Cell Peroxidase Interference in Competitive ELISA(Post)QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the
FAO Activity Negative Results? Data Analysis Help(Post)Quick answer On the Fatty Acid Oxidation (FAO) Assay Kit (BR00001), a researcher found that a subset of skeletal-muscle samples returned negative values once the control well was subtr
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research(Post)Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Six étapes pour un protocole ELISA sandwich reproductible en laboratoire(Post)Le protocole ELISA sandwich standard suit six étapes: revêtement du puits avec l’anticorps de capture, blocage, incubation des standards et échantillons, ajout de l’anticorps de détection, puis du
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
In Vitro vs In Vivo: Key Differences & When to Use Each(Post)In Vitro vs In Vivo: Complete Comparison + Selection Guide | Research MethodsDiscover the distinct roles of 'In Vivo' and 'In Vitro' in biological research, where one offers a natural con
5 étapes pour choisir une protéine de contrôle validée en laboratoire(Post)Utilisez une coloration protéine totale, comme le Ponceau S, quand vos traitements risquent de faire varier l’expression des protéines de ménage. Sinon, une protéine housekeeping validée pour votr
Dilutions 1:10 et 1:100 : détecter l'effet crochet en ELISA en labo(Post)L’effet crochet est une chute paradoxale du signal ELISA lorsque la concentration d’analyte devient trop élevée, ce qui produit un résultat faussement bas, voire négatif. Il touche surtout les for
Techniciens/chercheurs : choisir plaque ELISA selon liaison et optique(Post)Techniciens/chercheurs : choisir plaque ELISA selon liaison et optique Pour la plupart des ELISA colorimétriques, choisissez une plaque en polystyrène claire à surface de liaison moyenne ou élevée se
Avant le premier pipetage : plan expérimental ELISA, modèles copiables(Post)Un plan expérimental ELISA fiable repose sur six éléments non négociables: des contrôles complets (blanc, négatif, positif, matrice), des étalons pour la courbe de calibration, une série de diluti
Trained Immunity: How Your Innate Immune System Learns and Remembers(Post)For decades, immunologists believed that only adaptive immunity—the sophisticated system of T cells and B cells—could form lasting memories of past infections. The innate immune system, our body's fir
Comment choisir une protéine cytokine pour votre étude(Post)Comment choisir une protéine cytokine pour votre étude Pour une mesure fonctionnelle in vitro, privilégiez une cytokine recombinante à activité biologique validée sur la lignée cible. Pour une admini